Previous close | 19.99 |
Open | 20.06 |
Bid | 19.69 x 100 |
Ask | 19.75 x 200 |
Day's range | 19.47 - 20.12 |
52-week range | 10.29 - 22.09 |
Volume | |
Avg. volume | 422,613 |
Market cap | 1.393B |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | 98.65 |
EPS (TTM) | 0.20 |
Earnings date | 30 Apr 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.25 |
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals ( NASDAQ:KNSA ) Full Year 2023 Results Key Financial Results Revenue: US$270.3m (up 23% from FY...